Skip to search formSkip to main contentSkip to account menu

efalizumab

Known as: anti alphaL integrin, antiCD11 alpha, efalizumab [Chemical/Ingredient] 
A humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with… 
National Institutes of Health

Related topics

Related topics

4 relations
Monoclonal Antibodiesantigen bindinghu1124

Narrower (1)

Raptiva

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Weight gain and tumour necrosis factor‐alpha inhibitors in patients with psoriasis
To compare the effect of anti‐tumour necrosis factor (TNF)‐α therapies with agents that do not target TNF‐α on bodyweight and… 
Review
2009
Review
2009
Efalizumab discontinuation: A practical strategy
Efalizumab is a recombinant, humanized IgG1 monoclonal antibody used in the treatment of plaque psoriasis. Efalizumab… 
2008
2008
Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen.
Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from blood into tissue… 
Review
2007
Review
2007
Novel immunosuppression: small molecules and biologics.
2007
2007
Efalizumab in routine use: a clinical experience
With the advent of biological therapies, continuous long‐term control of psoriasis is now becoming a reality. We report our… 
2007
2007
Exacerbation of Pityriasis Rubra Pilaris under Efalizumab Therapy
A 60-year-old woman, diagnosed as having psoriasis vulgaris in 2004 and unresponsive to standard therapies, received weekly… 
2007
2007
Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
Pityriasis rubra pilaris has no single effective therapy and there are some cases resistant to multiple treatments. Psoriasis has… 
2006
2006
Treatment of recalcitrant dermatomyositis with efalizumab.
Dermatomyositis (DM) is an auto-immune disease that primarily affects muscles and skin. Muscle weakness appears in the shoulders… 
2003
2003
Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis
Background: Phase I and Phase II studies in patients with moderate to severe plaque psoriasis demonstrated that intravenous (IV… 
Review
2003
Review
2003
Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab
An improved understanding regarding the pathophysiology of psoriasis, coupled with advances in molecular research, has prompted… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)